State of the Art: Lung Cancer in 2021

State of the Art: Lung Cancer in 2021

Regular price
Sale price
Sold out
Unit price




This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer. We will start with an outstanding international example of tobacco control, discuss guidelines and practical tips for lung cancer screening, the new staging system and use of biomarkers for lung cancer detection and disease progression. The treatment of early stage, locally advanced and metastatic disease will be addressed, highlighting novel/minimally invasive approaches as well as the use, and toxicities of immunotherapy. Advancements in the evaluation and treatment of carcinoid and atypical carcinoid will also be highlighted. Interactive tumor boards will be held to highlight main teaching points and facilitate audience engagement. 

CME credits and/or Certificates of Completion are not provided for this session.

1- Improve the use of CT screening in your practice setting/community

2- Integrate new treatment options for patients with stage III lung cancer

3- Gain new findings about the toxicities of immunotherapy

Panagis Galiatsatos, DrMed: BIG Tobacco and Electronic Nicotine Delivery Systems: Preventing Another Epidemic

Renda S. Wiener, MD, MPH: Lung Cancer Screening: The Data and the Disconnect

Anne Valerie. Gonzalez, MD, MSc, MUHC: Lung Cancer Staging: Past, Present, and Future

Kazuhiro Yasufuku, MD: Pro/Con: Surgery Remains the Best Option for Early Stage Disease

James Urbanic, MD: SBRT Is the Best Option for Early Stage Disease

Frank Detterbeck, MD: The Heterogeneity of Stage III Disease

Tobias Peikert, MD: The Good: Immunotherapy in Lung Cancer from Neo-Adjuvant to Advanced-Stage Disease

Karthik Suresh, MD: The Bad: Recognizing and Managing Immune-Related Toxicity

Shetal Patel, MD, MSc: Targeted Therapy in Stage IV Disease

M. Patricia Rivera, MD, ATSF: Oligometastatic Disease

David J. Feller-Kopman, MD, DHMC: Typical and Atypical Carcinoid

Sandip P. Patel, MD. : Lung Cancer in the Elderly, Minority and Female Populations

You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!